Although the information that HDAC6 is involved in the etiopathogenesis of Alzheimer’s disease has appeared relatively recently and little is known about its pathomechanisms, the data discovered to date allow us to consider this regulatory protein as a promising therapeutic target for the treatment of neurodegenerative disorders. Here, HDAC6 is linked to early-onset autosomal dominant Alzheimer disease.